CVRx Inc Aktie News

CVRx (NASDAQ: CVRX ) stock is falling hard on Wednesday after posting results from its earnings report for the first quarter of 2024. The bad news for investors in CVRX stock starts with its earnings per share of 0$1.04.

CVRx, Inc. (NASDAQ:CVRX ) Q1 2024 Earnings Conference Call April 30, 2024 5:00 PM ET Company Participants Mike Vallie - IR Kevin Hykes - President and CEO Jared Oasheim - CFO Conference Call Participants Lilia-Celine Lozada - JPMorgan Phillip Dantoin - Piper Sandler Margaret Kaczor - William Blair Bill Plovanic - Canaccord Frank Takkinen - Lake Street Capital Markets Chase Knickerbocker - Craig...

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024.

MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after...

BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference

MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent wi...

CVRx, Inc. (CVRX) Q4 2023 Earnings Call Transcript

MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2023, and affirmed its 2024 business outlook.